Having optic neuritis — inflammation of the nerves that relay information between the eyes and the brain — as a…
Margarida Maia, PhD
Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Maia, PhD
Achieving nine goals could help address inequities with access to properly diagnosing and treating neuromyelitis optica spectrum disorder (NMOSD),…
Uplizna (inebilizumab) reduces the number and size of subclinical lesions — those that cause no apparent symptoms — in…
Testing positive for self-reactive antibodies causing both neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD)…
Starting treatment with off-label rituximab soon after neuromyelitis optica spectrum disorder (NMOSD) symptoms begin may prevent long-term disability worsening,…
Neuromyelitis optica spectrum disorder (NMOSD) may begin to manifest as uncontrollable nausea, vomiting, or hiccups — a condition referred…
Eye scans of people with neuromyelitis optica spectrum disorder (NMOSD) revealed they may have a thicker retina — the…
Undergoing plasma exchange, a blood-cleaning procedure, within 10 days after a relapse of neuromyelitis optica spectrum disorder (NMOSD) may…
Glial fibrillary acidic protein (GFAP) and the ubiquitin carboxy-terminal hydrolase L1 (UCHL1) enzyme appear to get shed into the bloodstream…
People who develop neuromyelitis optica spectrum disorder (NMOSD) later in life may go on to experience worse outcomes than…